Drug Stents: J&J Innovates, Others Stumble

In traditional coronary stents, Cordis/J&J initially dominated the market, only to dramatically lose market share because of its inability to come up with a next generation product quickly enough, before becoming competitive again. In drug-eluting stents, which look to be the next blockbuster cardiovascular product, J&J again has an early lead, but this time its competitors have stumbled.

More from Innovation

More from In Vivo